IASIS PHARMA has launched a new pharmaceutical product under the brand name Licepler (Eplerenone). Licepler is specifically indicated for the reduction of risk of cardiovascular death in people with heart failure and left ventricular dysfunction ≤40% after a recent acute myocardial infarction, in combination with standard therapies and as treatment against hypertension. Licepler (25mg/f.c. tab and 50mg/f.c. tab) is the 1st generic eplerenone, which has been successfully launched in the Greek pharmaceutical market by a Greek pharmaceutical industry.
RABEREN/ΙΑSIS PRESS RELEASE28/04/2014
ΑVALSAN PLUS PRESS RELEASE10/02/2014